Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 130

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 130
---
’s supply of Tisseel under the Agreement for manufacturing of GelrinC.

Under the Services Agreement,
Baxter provides us with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for all such
support. In consideration for receiving such support, we pay Baxter $60,000 per year until we receive FDA approval to market GelrinC
in the United States. If we exceed the 40 hours limit, Baxter will charge us $2,500 per any additional hour. Following FDA approval to
market GelrinC in the United States, we shall pay Baxter $200,000 per year during the term of this Services Agreement.

The Services Agreement has
an initial term of 5 years and is automatically renewable for consecutive 5 years term. According to the Service Agreement, it at any
time during the term of the Service Agreement, we decide in good faith to commence negotiations with any third party for the acquisition
of all or substantially all of our stock or assets, we shall provide a written notice to Baxter at least 10 business day in advance of
commencing such negotiations.

In March 2022, following
Baxter establishing a local subsidiary in Israel, Teva was taken out of the Service Agreement and we are, since then, sourcing Tisseel
kits from Baxter Israel directly without change in any of the terms.

Competition

We are currently unaware
of any off-the-shelf product solutions in the market for cartilage knee repair. There are two main procedures available and already discussed
in this prospectus:

| (i) | microfracture,                
 which is non-proprietary, and |

| (ii) | (ii) MACI, an autologous                                                                                                                   
 cellular (patient’s own cells) treatment procedures available from Vericel Corp., or Vericel, which is the only commercial                 
 offering in the U.S. market. If approved, GelrinC will compete in this market based on its already outlined advantages as an off-the-shelf 
 highly cost-effective product. There are also “modified human tissue” products that are based on allogeneic cartilage                      
 matter – BioCartilage, from Arthrex GmbH, which is a paste mixed with PRP (platelet rich plasma or minced cartilage tissue)                
 and Revaflex, a diced cadaver cartilage from ISTO Technologies Inc. These products are often dependent on cadaver tissue and are           
 not frequently used across the patient population.